First Circuit Affirms Dismissal Of Putative Securities Fraud Class Action, Finding Defendants' Statements Concerning The Potential NDA For A Drug Candidate Came "Replete with Caveats"

by Shearman & Sterling LLP

On August 22, 2017, the United States Court of Appeals for the First Circuit affirmed an order from the District of Massachusetts, dismissing a putative securities class action that asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder against drug maker Sarepta Therapeutics Inc. (“Sarepta”) and certain of its current and former officers.  Corban, et al. v. Sarepta Pharmaceutical Inc., et al., No. 16-1658 (1st Cir. Aug. 22, 2017).  The complaint alleged that Sarepta deceived investors about the significance of trial data for the company’s new muscular dystrophy drug, eteplirsen, and the likelihood that the company would obtain United States Food and Drug Administration (“FDA”) approval for that drug.  The First Circuit held that plaintiffs failed to plead a “cogent inference of scienter” that Sarepta misled investors, and also held that while opinions implying false facts may suffice to allege a fraud claim, the opinions at issue were insufficient because they “came replete with caveats.”
The allegations in plaintiffs’ amended complaint focused primarily on Sarepta’s statements in its July 24, 2013 press release and related comments by its officers regarding a meeting Sarepta had with the FDA.  According to plaintiffs, these communications paved the company’s path to commit fraud because Sarepta allegedly disclosed too little of the concerns raised by the FDA and instead painted “too rosy” a picture of the FDA’s reaction to Sarepta’s trial data for eteplirsen.  For example, the amended complaint cited statements by Sarepta’s CEO that he was “very encouraged by the FDA feedback,” that he was hopeful that the FDA “would accept [an NDA] for filing,” and that the FDA was “open to considering an NDA filing based on the data [Sarepta had] shared with [the FDA] to date.”  Plaintiffs alleged that these statements were misleading because they failed to warn investors about “a number of concerns” of the FDA, and failed to disclose that the FDA had articulated “strong reservations” about the type of data upon which Sarepta was relying.
In denying plaintiffs’ appeal and affirming the lower court’s dismissal of the action, the First Circuit noted that “[t]he challenged statements that mark the beginning of the class period provide poor material for building a fraud claim,” because they “convey opinion more than fact.”  The First Circuit recognized that while an opinion that implies a false fact may suffice to state a claim under Section 10(b), the opinions at issue in this case “came replete with caveats” that contradicted plaintiffs’ claim that the statements were misleading and unduly optimistic.  In particular, the Court found that the following caveats “cut against the inference of scienter”:  (1) Sarepta’s CEO accurately reported that the FDA declined to offer “any guarantee or assurance that an NDA submission would be acceptable for filing,” (2) Sarepta’s stock price dropped nineteen percent after the CEO’s “mix of optimism and caution was communicated to investors,” and (3) three weeks following the July 24, 2013 press release, Sarepta reminded investors that it had been trying to convince the FDA that its method for quantifying a key protein essential for muscle function was acceptable and preferable, but acknowledged that its data set was limited.  The First Circuit observed that “[a]t worst, there was positive spin that put more emphasis in tone and presentation on the real signs of forward movement with the NDA than it did on causes for wondering if the journey would prove successful.”
The First Circuit further found that plaintiffs “misse[d] the mark” in adequately alleging material omissions to support their fraud claim because they merely pointed to details allegedly omitted from Sarepta’s statements but failed to explain how any of the alleged omitted details rendered the particular disclosures misleading.  The Court noted that mere possession of nonpublic information does not create a duty to disclose it, and further that defendants “had no legal obligation to loop the public into each detail of every communication with the FDA.”  Thus, the First Circuit found that defendants’ alleged failure to mention specific factors contributing to the FDA’s position, “while nonetheless faithfully representing that position (including by quoting directly from FDA sources at times), strikes us as more consistent with negligence than reckless or intentional concealment.”  Moreover, the Court rejected plaintiffs’ argument that Sarepta’s $125 million offering of common stock in July 2013 established a motive of scienter, finding that “something more” was required than the ordinary and “ever-present desire” to improve financial results.  Contrary to plaintiffs’ allegation that defendants needed this offering to provide Sarepta “essential funding,” the Court found that at the time of the July 2013 offering Sarepta had not been in dire financial condition but instead had sufficient cash, cash equivalents and working capital. 
Accordingly, in affirming the dismissal of the Section 10(b) and 20(a) claims, the Court held that it did not find “the malicious inference” to be “at least as compelling as any opposing innocent inference.”  Noting that the FDA ultimately did accept the NDA for filing in 2015 and granted accelerated approval for eteplirsen in 2016 after this litigation was underway, the Court concluded that “more plausible is the opposing innocent inference that the defendants, perhaps negligently, waxed too optimistically about the FDA’s expression of a willingness to consider an NDA for eteplirsen while emphasizing too little the FDA’s reservations about such an application.  This is simply a case in which the complaint focuses too much on nuance rather than false facts or material omissions to support the necessary strong inference of scienter.”

Written by:

Shearman & Sterling LLP

Shearman & Sterling LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.